OCUL Valuation

Ocular Therapeutix Inc

Add to Watchlist

Advanced Chart

10.850

+0.22(2.070%)1D

OCUL Relative Valuation

OCUL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OCUL is overvalued; if below, it's undervalued.

Historical Valuation

Ocular Therapeutix Inc (OCUL) is now in the Fair zone, suggesting that its current forward PS ratio of 10.85 is considered Fairly compared with the five-year average of -11.31. The fair price of Ocular Therapeutix Inc (OCUL) is between 7.75 to 22.74 according to relative valuation methord.

Relative Value

Fair Zone

7.75-22.74

Current Price：10.85

Fair

-7.51

Trailing

Forward

-7.79

EV/EBITDA

Ocular Therapeutix Inc. (OCUL) has a current EV/EBITDA of -7.79. The 5-year average EV/EBITDA is -6.81. The thresholds are as follows: Strongly Undervalued below -17.60, Undervalued between -17.60 and -12.21, Fairly Valued between -1.41 and -12.21, Overvalued between -1.41 and 3.99, and Strongly Overvalued above 3.99. The current Forward EV/EBITDA of -7.79 falls within the Historic Trend Line -Fairly Valued range.

-7.57

EV/EBIT

Ocular Therapeutix Inc. (OCUL) has a current EV/EBIT of -7.57. The 5-year average EV/EBIT is -7.27. The thresholds are as follows: Strongly Undervalued below -20.03, Undervalued between -20.03 and -13.65, Fairly Valued between -0.89 and -13.65, Overvalued between -0.89 and 5.49, and Strongly Overvalued above 5.49. The current Forward EV/EBIT of -7.57 falls within the Historic Trend Line -Fairly Valued range.

10.85

Ocular Therapeutix Inc. (OCUL) has a current PS of 10.85. The 5-year average PS is 13.69. The thresholds are as follows: Strongly Undervalued below -5.04, Undervalued between -5.04 and 4.33, Fairly Valued between 23.06 and 4.33, Overvalued between 23.06 and 32.43, and Strongly Overvalued above 32.43. The current Forward PS of 10.85 falls within the Historic Trend Line -Fairly Valued range.

-10.20

P/OCF

Ocular Therapeutix Inc. (OCUL) has a current P/OCF of -10.20. The 5-year average P/OCF is -9.91. The thresholds are as follows: Strongly Undervalued below -20.03, Undervalued between -20.03 and -14.97, Fairly Valued between -4.84 and -14.97, Overvalued between -4.84 and 0.22, and Strongly Overvalued above 0.22. The current Forward P/OCF of -10.20 falls within the Historic Trend Line -Fairly Valued range.

-10.82

P/FCF

Ocular Therapeutix Inc. (OCUL) has a current P/FCF of -10.82. The 5-year average P/FCF is -10.29. The thresholds are as follows: Strongly Undervalued below -27.11, Undervalued between -27.11 and -18.70, Fairly Valued between -1.87 and -18.70, Overvalued between -1.87 and 6.54, and Strongly Overvalued above 6.54. The current Forward P/FCF of -10.82 falls within the Historic Trend Line -Fairly Valued range.

Ocular Therapeutix Inc (OCUL) has a current Price-to-Book (P/B) ratio of 7.35. Compared to its 3-year average P/B ratio of 19.74 , the current P/B ratio is approximately -62.76% higher. Relative to its 5-year average P/B ratio of 7.20, the current P/B ratio is about 2.15% higher. Ocular Therapeutix Inc (OCUL) has a Forward Free Cash Flow (FCF) yield of approximately -0.09%. Compared to its 3-year average FCF yield of -14.55%, the current FCF yield is approximately -99.41% lower. Relative to its 5-year average FCF yield of -13.32% , the current FCF yield is about -99.35% lower.

7.35

P/B

Median3y

19.74

Median5y

7.20

-0.09

FCF Yield

Median3y

-14.55

Median5y

-13.32

Competitors Valuation Multiple

The average P/S ratio for OCUL's competitors is 18.66, providing a benchmark for relative valuation. Ocular Therapeutix Inc Corp (OCUL) exhibits a P/S ratio of 10.85, which is -41.84% above the industry average. Given its robust revenue growth of -5.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

OCUL.O

Ocular Therapeutix Inc

Agios Pharmaceuticals Inc

Sarepta Therapeutics Inc

Catalyst Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

19.26

132.98%

2.44B

Performance Decomposition

Market capitalization of OCUL increased by 9.71% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -236.58 to -477.30.

The secondary factor is the Revenue Growth, contributed -5.71%to the performance.

Overall, the performance of OCUL in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-5.71%

15.43M → 14.54M

Revenue Growth

101.75%

-236.58 → -477.30

Margin Expansion

-86.33%

-55.17 → -7.54

P/E Change

9.71%